CTOs on the Move

Encore Dermatology

www.encorederm.com

 
Headquartered in Malvern, Pennsylvania, Encore Dermatology is a privately held fully integrated dermatology company with a mission committed to delivering innovative prescription therapies and medical devices to dermatologists focusing on customer service and improving the quality-of-life of patients.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.encorederm.com
  • 5 Great Valley Pkwy Suite 200
    Malvern, PA USA 19355
  • Phone: 844.848.6543

Executives

Name Title Contact Details

Funding

Encore Dermatology raised $20M on 04/08/2019

Similar Companies

Capital i

BeClinic | Best WordPress theme for clinics and medicine

GuideStar Clinical

GuideStar works with hospitals, health systems and physician practices around the country to build, manage and support clinical research programs. From helping incorporate a clinical trial strategy to providing management guidance and support, our service delivery is based on operational and financial best practices to ensure optimal results for research programs.

Tobira Therapeutics

Tobira Therapeutics is a clinical-stage biopharmaceutical company developing cenicriviroc (CVC), an oral potent dual inhibitor of chemokine receptors CCR2 and CCR5. Tobira is initiating a Phase 2 clinical trial of cenicriviroc for the treatment of Nonalcoholic Steatohepatitis (NASH), a leading cause of cirrhosis and liver transplant. The company has also completed a Phase 2b clinical trial of cenicriviroc in 143 HIV-infected subjects, and the compound is positioned for Phase 3 studies as a novel, once daily, fixed-dose cenicriviroc/lamivudine backbone as part of combination HIV therapy. Tobira is backed by a syndicate of leading life science investors including Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners, Novo Ventures and Canaan Partners.

Pipeline Therapeutics

Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair. The company`s lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor (GSI) to treat mild-to-moderate sensorineural hearing loss (SNHL) associated with cochlear synaptopathy. The company also has a portfolio of programs, including PIPE-307, focused on remyelination and axonal repair, to address a range of neurological disorders, including multiple sclerosis.

Fluid Air

Fluid Air is a Aurora, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.